Clinical trials: SARS-CoV-2 Virus Infection
Respiratory Disease
QIAstat-Dx® Respiratory Panel Plus (RPP) Clinical Performance Study
This study will evaluate the clinical performance of the QIAstat-Dx® Respiratory Panel Plus (RPP) SARS-CoV-2 target with a validated comparator method
- Trial name
- NCT05733559
- Testing
- QIAstat-Dx® Respiratory Panel Plus (RPP)
- Where
- United Kingdom
- Volunteers
- 565 people
- Sponsor
- QIAGEN Gaithersburg, Inc
COVID-19
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.
- Trial name
- NCT06175494
- Testing
- Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- Where
- China
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
- Trial name
- NCT04410354
- Testing
- Merimepodib, Remdesivir
- Where
- 10 sites in United States
- Volunteers
- 44 people
- Sponsor
- ViralClear Pharmaceuticals, Inc.
SARS-COV2 Infection
Validation of HyperDetector for SARS-CoV-2
To evaluate the HyperDetector as a method to rapidly screen SARS-CoV-2 To determine the sensitivity and specificity of the screening assay performed on oral swab and saliva specimens, compared to a validated RT-PCR COVID-19…
- Trial name
- NCT05124496
- Testing
- Screening Device
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- HyperSpectral APD
COVID-19
Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19
This is a phase 2 randomized, double-blind clinical trial testing an anti-SARS-CoV-2 COVID-19 vaccine (AV-COVID-19) made on site using PT AIVITA Biomedika Indonesia's vaccine-enabling kit for the prevention of COVID-19 infection.
- Trial name
- NCT05007496
- Testing
- AV-COVID-19
- Where
- Indonesia
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Aivita Biomedical, Inc.
Sars-CoV-2 Infection
A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19
The innovative drug XC221 100 mg tablet is designed for the treatment of COVID-19 (SARS-CoV-2 infection). A multicenter, adaptive, randomized, double-blind, placebo-controlled Phase III clinical study is aimed to assess the…
- Trial name
- NCT04940182
- Testing
- XC221
- Where
- 11 sites in Russia
- Volunteers
- 274 people
- Sponsor
- RSV Therapeutics LLC
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Study of Varespladib in Patients Hospitalized With Severe COVID-19
This is a 2-part, multi-center, randomized, double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability, and efficacy of oral varespladib, in addition to standard of care, in patients…
- Trial name
- STAIRS (NCT04969991)
- Testing
- Varespladib
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ophirex, Inc.
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
SARS-CoV2 Infection
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood…
- Trial name
- NCT05338762
- Where
- 5 sites in United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- MiCo BioMed Co., Ltd.
Covid19
Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test
Performance of the LumiraDx SARS-CoV-2 Ag assay will be assessed by comparison to a reference method.
- Trial name
- ASPIRE (NCT04557046)
- Testing
- Nasal Swab, Nasopharyngeal swab, Throat swab
- Where
- 7 sites in United States
- Volunteers
- 1,134 people
- Sponsor
- LumiraDx UK Limited
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd
Covid-19 Disease
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
Adult female and male patients, hospitalized with Covid-19 infection (confirmed by reverse transcription polymerase chain reaction [RT-PCR]), will be screened for participation in this prospective, multi-center, double-blind…
- Trial name
- NCT04682873
- Testing
- Enisamium Iodide
- Where
- 13 sites in Ukraine
- Volunteers
- 592 people
- Sponsor
- Joint Stock Company "Farmak"
Covid19
Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents
This Phase 1 trial is an open-label trial to evaluate the safety, reactogenicity and immunogenicity of two dosages (10^6 PFU and 10^7 PFU) of intranasal CVXGA1 administered as a single dose in healthy adults age 18-55 years and…
- Trial name
- CVXGA1-001 (NCT04954287)
- Testing
- CVXGA1 low dose, CVXGA1 high dose
- Where
- 4 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID19
Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19
This randomized, Phase I/II feasibility study will evaluate the safety and efficacy of the RD-X19 device in SARS-CoV-2 infected individuals with uncomplicated COVID-19.
- Trial name
- NCT04662671
- Testing
- RD-X19
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- EmitBio Inc.
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
SARS-CoV-2
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGE
The main objective of the surveillance is to evaluate the incidence of the adverse events (AEs), and other safety-related information in South-Korean population.
- Trial name
- NCT06333704
- Testing
- SPIKEVAX Bivalent BA.1, SPIKEVAX Bivalent BA.4/5, SPIKEVAX XBB.1.5
- Where
- 26 sites in South Korea
- Volunteers
- 4,207 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19, Sars-CoV-2 Infection
Performance Study of SONA Saliva C-19 Rapid Test
The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to a RT-PCR reference method
- Conditions
- Covid19, Sars-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT04877002
- Testing
- Sona Saliva C-19 Rapid Test
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sona Nanotech Inc
COVID-19
A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19
This is a phase 1b, randomized, double-blind, positive control trial in healthy adults, intended to evaluate the safety and immunogenicity profile of RQ3013 in healthy adults primed with a two-dose inactivated vaccine 6-9 months…
- Trial name
- NCT05396573
- Testing
- RQ3013, Comirnaty
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Walvax Biotechnology Co., Ltd.
COVID-19 Respiratory Infection, COVID-19
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 Patients
The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR.
- Trial name
- NCT06452069
- Testing
- IMMUNO19
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Biodex S.A